List of Pemazyre drug patents

Pemazyre is owned by Incyte Corp.

Pemazyre contains Pemigatinib.

Pemazyre has a total of 3 drug patents out of which 0 drug patents have expired.

Pemazyre was authorised for market use on 17 April, 2020.

Pemazyre is available in tablet;oral dosage forms.

Pemazyre can be used as for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement, treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering once daily a tablet containing about 0.5 mg to about 10 mg of pemigatinib; treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib qd for 14 days then not administering pemigatinib for 7 days in a 21-day cycle; treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib in a daily dose of about 5 mg to about 20 mg.

Drug patent challenges can be filed against Pemazyre from 2024-04-17.

The generics of Pemazyre are possible to be released after 03 May, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9611267 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jan, 2035

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10131667 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors
Jun, 2033

(10 years from now)

US11466004 INCYTE CORP Solid forms of an FGFR inhibitor and processes for preparing the same
May, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
Orphan Drug Exclusivity (ODE) Apr 17, 2027
New Indication (I) Aug 26, 2025

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: 2024-04-17

Market Authorisation Date: 17 April, 2020

Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement; Treatment of p...

Dosage: TABLET;ORAL

More Information on Dosage

PEMAZYRE family patents

15

United States

6

Japan

5

Israel

5

European Union

4

Australia

4

Lithuania

4

Hungary

4

Philippines

4

Argentina

4

Korea, Republic of

4

China

3

Denmark

3

Slovenia

3

Singapore

3

Croatia

3

Portugal

3

Spain

3

Peru

3

Poland

3

Chile

3

Taiwan, Province of China

3

RS

EA

3

EA

3

Canada

3

New Zealand

2

Costa Rica

2

Colombia

2

Brazil

2

Cyprus

2

Malaysia

2

Ecuador

2

Ukraine

2

ME

IB

1

IB

1

Mexico

1

Hong Kong

1

Morocco

1

Norway

1

Netherlands

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in